-
SANOFI-AVENTIS U.S. LLC et al v. MYLAN N.V. et al DC CAFC
- 2:17-cv-09105
- D.N.J.
- Judge: Stanley R. Chesler
+1
- Filed: 10/24/2017
- Closed: 11/02/2020
- Latest Docket Entry: 02/07/2022
- PACER
3
Plaintiffs
8
Defendants
2
Accused
Products
18
Patents-in-Suit
1,106
Days in
Litigation
-
SANOFI-AVENTIS U.S. LLC et al v. MYLAN N.V. et al DC CAFC
- 2:17-cv-09105
- D.N.J.
- Judge: Stanley R. Chesler
+1
- Filed: 10/24/2017
- Closed: 11/02/2020
- Latest Docket Entry: 02/07/2022
- PACER
Causes of Action
Infringement
Declaratory Judgment
Patent Infringement
Assigned Judge
Outcome Summary
Patent Information
-
Infringement
Biocon Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,603,044 B2 | All Asserted Claims |
No infringement
Entry 628
|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,679,069 B2 | All Asserted Claims |
No infringement
Entry 628
|
Biocon Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,603,044 B2 | All Asserted Claims |
No infringement
Entry 628
|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,679,069 B2 | All Asserted Claims |
No infringement
Entry 628
|
Biocon SA
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,603,044 B2 | All Asserted Claims |
No infringement
Entry 628
|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,679,069 B2 | All Asserted Claims |
No infringement
Entry 628
|
Biocon Sdn BHD
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,603,044 B2 | All Asserted Claims |
No infringement
Entry 628
|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,679,069 B2 | All Asserted Claims |
No infringement
Entry 628
|
Mylan GmbH
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,603,044 B2 | All Asserted Claims |
No infringement
Entry 628
|
| an insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mLan insulin glargine [rDNA origin] 100 u/mL for subcutaneous injection including a vial containing the active ingredient insulin glargine in 100 u/mL | US 8,679,069 B2 | All Asserted Claims |
No infringement
Entry 628
|